Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.

about

Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.

P2860

Q38643068-EBC66A85-0B7E-49BA-84BD-BE8C8CB979A9 Q47661007-0A04403A-824A-4F99-AFC6-1D440829CA80 Q47973033-AF3D5E41-F081-48D3-987C-06D84E350A3A

P2860

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.

Item

http://www.wikidata.org/entity/Q38780827

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Population Pharmacokinetics of ...... sing Hematologic Malignancies.

@en

type

Item

label

Population Pharmacokinetics of ...... sing Hematologic Malignancies.

@en

prefLabel

Population Pharmacokinetics of ...... sing Hematologic Malignancies.

@en

P1476

Population Pharmacokinetics of ...... sing Hematologic Malignancies.

@en

P2093

Baiteng Zhao

http://www.w3.org/2001/XMLSchema#string

Graham Jang

http://www.w3.org/2001/XMLSchema#string

Hong Li

http://www.w3.org/2001/XMLSchema#string

Naomi N Hunder

http://www.w3.org/2001/XMLSchema#string

Tae H Han

http://www.w3.org/2001/XMLSchema#string

P2860

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

Mechanism-based concepts of size and maturity in pharmacokinetics.

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.

Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates.

P304

1148-1158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.920

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28513851

http://www.w3.org/2001/XMLSchema#string

P932

5574006

http://www.w3.org/2001/XMLSchema#string

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.

about

P2860

P2860

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932